MA34326B1 - Formulation de poudre sèche comprenant un médicament antimuscarinique - Google Patents

Formulation de poudre sèche comprenant un médicament antimuscarinique

Info

Publication number
MA34326B1
MA34326B1 MA35474A MA35474A MA34326B1 MA 34326 B1 MA34326 B1 MA 34326B1 MA 35474 A MA35474 A MA 35474A MA 35474 A MA35474 A MA 35474A MA 34326 B1 MA34326 B1 MA 34326B1
Authority
MA
Morocco
Prior art keywords
dry powder
antimuscarinic
medicine
powder formulation
formulation
Prior art date
Application number
MA35474A
Other languages
English (en)
Inventor
Francesca Schiaretti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42942112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34326(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA34326B1 publication Critical patent/MA34326B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une formulation de poudre sèche adaptée pour l'administration par inhalation au moyen d'un inhalateur de poudre sèche, comprenant un médicament antimuscarinique en tant que substance active. L'invention concerne en outre le procédé pour la préparation de la formulation et son utilisation dans la prévention et/ou le traitement d'une large gamme d'affections comprenant des troubles respiratoires.
MA35474A 2010-06-22 2011-05-30 Formulation de poudre sèche comprenant un médicament antimuscarinique MA34326B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10166903 2010-06-22
PCT/EP2011/058804 WO2011160920A1 (fr) 2010-06-22 2011-05-30 Formulation de poudre sèche comprenant un médicament antimuscarinique

Publications (1)

Publication Number Publication Date
MA34326B1 true MA34326B1 (fr) 2013-06-01

Family

ID=42942112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35474A MA34326B1 (fr) 2010-06-22 2011-05-30 Formulation de poudre sèche comprenant un médicament antimuscarinique

Country Status (22)

Country Link
US (1) US20110308519A1 (fr)
EP (1) EP2585047A1 (fr)
JP (1) JP2013529606A (fr)
KR (1) KR20130111967A (fr)
CN (1) CN102946868B (fr)
AR (1) AR081967A1 (fr)
AU (1) AU2011269238A1 (fr)
BR (1) BR112012032330A2 (fr)
CA (1) CA2803418A1 (fr)
CL (1) CL2012003450A1 (fr)
CO (1) CO6640319A2 (fr)
EA (1) EA201291306A1 (fr)
MA (1) MA34326B1 (fr)
MX (1) MX2012014541A (fr)
NZ (1) NZ604983A (fr)
PE (1) PE20130282A1 (fr)
SG (1) SG186427A1 (fr)
TN (1) TN2012000566A1 (fr)
TW (1) TW201204412A (fr)
UA (1) UA107499C2 (fr)
WO (1) WO2011160920A1 (fr)
ZA (1) ZA201209682B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2154136A1 (fr) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Dérivés de carbone de quinuclidine et ses compositions médicales
EP2206712A1 (fr) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. Dérivés d'amino-ester d'alcaloïde et sa composition médicale
CA2803459A1 (fr) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Derives aminoester d'alcaloides et compositions medicinales les comprenant
CN102947298B (zh) * 2010-06-22 2016-03-02 奇斯药制品公司 生物碱氨基酯衍生物及其药物组合物
TR201105367A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
TR201205852A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Geliştirilmiş yeni kuru toz formülasyonu.
CN104011043B (zh) 2011-12-30 2016-11-16 奇斯药制品公司 作为抗毒蕈碱剂的1-氮杂杂环基乙酸的奎宁环酯、它们的制备方法及其药用组合物
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
GEP201706672B (en) 2012-07-05 2017-05-25 Arven Ilac Sanayi Ve Ticaret As Dry powder inhaler compositions comprising long acting muscorinic antagonists
BR112015010121A2 (pt) * 2012-11-30 2017-07-11 Hoffmann La Roche inibidores de quinase de tirosina de bruton
DK3409270T3 (da) 2013-07-11 2021-04-26 Chiesi Farm Spa Tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum til indgivelse ved inhalation
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
CN107569474A (zh) * 2016-07-04 2018-01-12 正大天晴药业集团股份有限公司 一种可吸入干粉形式的药物组合物所用的载体的制备方法
EP3833964B1 (fr) * 2018-08-07 2023-07-26 Norton (Waterford) Limited Application de spectroscopie raman pour la fabrication de poudres à inhaler
IT201800007928A1 (it) * 2018-08-07 2020-02-07 Sofar Spa Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio
JP2023539073A (ja) 2020-08-14 2023-09-13 ノートン （ウォーターフォード） リミテッド プロピオン酸フルチカゾンと硫酸アルブテロールの吸入製剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200102567T2 (tr) 1999-03-05 2002-01-21 Chiesi Farmaceutici S.P.A. İnhalasyon için geliştirilmiş toz halindeki farmasötik bileşimler
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
WO2002000197A1 (fr) 2000-06-27 2002-01-03 Vectura Limited Procede permettant de produire des particules destinees a etre utilisees dans une composition pharmaceutique
IL156499A0 (en) 2000-12-22 2004-01-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
MXPA04006206A (es) 2001-12-20 2004-12-06 S A L V A T Lab Sa Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.
ES2359576T5 (es) 2002-07-31 2020-03-03 Chiesi Farm Spa Inhalador de polvo
MXPA05001903A (es) * 2002-08-21 2005-04-28 Norton Healthcare Ltd Composicion para inhalacion.
UY28871A1 (es) * 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1882691A1 (fr) * 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Dérivés de quinuclidine comme antagonistes M3
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376

Also Published As

Publication number Publication date
EP2585047A1 (fr) 2013-05-01
EA201291306A1 (ru) 2013-05-30
CL2012003450A1 (es) 2013-03-15
KR20130111967A (ko) 2013-10-11
CN102946868B (zh) 2014-10-29
TN2012000566A1 (en) 2014-04-01
AR081967A1 (es) 2012-10-31
PE20130282A1 (es) 2013-03-25
CO6640319A2 (es) 2013-03-22
WO2011160920A1 (fr) 2011-12-29
MX2012014541A (es) 2013-01-29
TW201204412A (en) 2012-02-01
US20110308519A1 (en) 2011-12-22
CA2803418A1 (fr) 2011-12-29
NZ604983A (en) 2014-07-25
SG186427A1 (en) 2013-01-30
UA107499C2 (uk) 2015-01-12
JP2013529606A (ja) 2013-07-22
CN102946868A (zh) 2013-02-27
AU2011269238A1 (en) 2013-01-10
ZA201209682B (en) 2014-03-26
BR112012032330A2 (pt) 2016-11-08

Similar Documents

Publication Publication Date Title
MA34326B1 (fr) Formulation de poudre sèche comprenant un médicament antimuscarinique
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
IL273194B2 (en) Methods, compounds and preparations for the treatment of parainfluenza virus in patients with a deficiency in the immune system
NZ701915A (en) High-concentration monoclonal antibody formulations
MX2011013150A (es) Composicion farmaceutica para uso en oftalmologia medica y veterinaria.
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA33295B1 (fr) Nouvelle formulation de diclofénac
Zhou et al. Allicin protects rat cortical neurons against mechanical trauma injury by regulating nitric oxide synthase pathways
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
US20180015054A1 (en) Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
JP2015524423A5 (fr)
BR112012028047A2 (pt) sistema de cateter, cateter, método de administração de um agente a um paciente e método para variar uma dosagem de um agente ativo
MX2013003523A (es) Composicion farmaceutica de dosis baja.
EA201591768A1 (ru) Дозированные препараты в качестве модуляторов опиоидного рецептора
CN103877005A (zh) 一种复方奥氮平皮下埋植缓释剂
SA518392177B1 (ar) نظام إرتواء
CN104414968A (zh) 一种左氧氟沙星单剂量滴眼液及其制备方法
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
NZ596881A (en) Phentermine liquid dosage form
US20230372264A1 (en) Composition for the prevention of infection by sars-cov-2
Blassmann Linezolid/rifampicin interaction